NASDAQ:GLYCGlycoMimetics Stock Price, Forecast & News

GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GLYC stock has decreased by 3.7% and is now trading at $2.83. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GlycoMimetics.

GlycoMimetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for GlycoMimetics.

GlycoMimetics Inc (NASDAQ:GLYC) issued its earnings results on Friday, May, 1st. The biotechnology company reported ($0.18) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.12. The biotechnology company had revenue of $9 million for the quarter. View GlycoMimetics' earnings history.

6 brokers have issued 12-month price targets for GlycoMimetics' shares. Their forecasts range from $5.00 to $16.00. On average, they expect GlycoMimetics' stock price to reach $8.75 in the next year. This suggests a possible upside of 209.2% from the stock's current price. View analysts' price targets for GlycoMimetics.

Media stories about GLYC stock have trended negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutGlycoMimetics.

GlycoMimetics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 2,880,000 shares, a decline of 6.8% from the March 31st total of 3,090,000 shares. Based on an average daily trading volume, of 257,300 shares, the short-interest ratio is currently 11.2 days. Currently, 8.6% of the shares of the stock are sold short. View GlycoMimetics' Current Options Chain.

Some companies that are related to GlycoMimetics include NewLink Genetics (NLNK), Urogen Pharma (URGN), Organogenesis (ORGO), Emisphere Technologies (EMIS), BioDelivery Sciences International (BDSI), Trillium Therapeutics (TRIL), BioSpecifics Technologies (BSTC), DURECT (DRRX), Neoleukin Therapeutics (NLTX), Beyondspring (BYSI), VBI Vaccines (VBIV), Protagonist Therapeutics (PTGX), Satsuma Pharmaceuticals (STSA), Flexion Therapeutics (FLXN) and Fulcrum Therapeutics (FULC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Vanda Pharmaceuticals (VNDA), Exelixis (EXEL), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO) and Fate Therapeutics (FATE).

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (11.09%), BlackRock Inc. (6.36%), Invesco Ltd. (5.48%), State Street Corp (1.43%), Geode Capital Management LLC (1.19%) and Morgan Stanley (1.10%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius and John L Magnani. View institutional ownership trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Redmile Group LLC, AXA, BlackRock Inc., Parametric Portfolio Associates LLC, Athanor Capital LP, UBS Group AG, and State Street Corp. View insider buying and selling activity for GlycoMimetics.

GLYC stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Federated Hermes Inc., Morgan Stanley, Two Sigma Advisers LP, Two Sigma Investments LP, Wells Fargo & Company MN, AQR Capital Management LLC, and Geode Capital Management LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius. View insider buying and selling activity for GlycoMimetics.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GLYC stock can currently be purchased for approximately $2.83.

GlycoMimetics has a market capitalization of $123.33 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.

The official website for GlycoMimetics is www.glycomimetics.com.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]